Skip to main content

Table 1 Study population

From: Evaluation of the safety and efficacy of a novel Anatomical classification and dUal anchoRing theory to Optimize the tavR strategy for pure severe Aortic regurgitation (AURORA): a prospective cohort study

Inclusion criteria

1. Patients with pure severe AR diagnosed by echocardiography

2. > 65 years old

3. Patients with high surgical risk and surgical contraindications discussed by heart team

4. Multi-director computed tomography (MDCT) multiplanar measurements are complete

5. Informed consent form

Exclusion criteria

1. Patients with AS diagnosed by echocardiography

2. LVEF < 20% and LVEDD > 70 mm

3. Other contraindications for TAVR:

 Subjects with bacteremia or toxemia; active endocarditis; any intracardiac mass, left ventricular or atrial thrombus, vegetation diagnosed by echocardiography; severe mitral or tricuspid valve regurgitation; severe allergy to contrast agent, aspirin, heparin, thiazide, nickel-titanium memory alloy; other serious diseases that may reduce the life expectancy to less than 12 months; severe coagulation dysfunction; abdominal or thoracic aortic aneurysm; other conditions that the investigators determine are not suitable for this clinical study

4. Poor patient compliance, unable to complete the study as required

5. Have participated in other interventional clinical trials (within the past 30 days)